ClinVar Miner

Submissions for variant NM_000719.7(CACNA1C):c.6329dup (p.Glu2111fs)

dbSNP: rs771708175
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine RCV000454638 SCV000538551 uncertain significance not specified 2016-04-25 criteria provided, single submitter clinical testing Variant identified in a genome or exome case(s) and assessed due to predicted null impact of the variant or pathogenic assertions in the literature or databases. Disclaimer: This variant has not undergone full assessment. The following are preliminary notes: LOF not a known disease mechanism for CACNA1C ; ExAC: 2/57170 European chromosomes
Labcorp Genetics (formerly Invitae), Labcorp RCV000477263 SCV000553027 uncertain significance Long QT syndrome 2024-01-11 criteria provided, single submitter clinical testing This sequence change creates a premature translational stop signal (p.Glu2111Argfs*15) in the CACNA1C gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 28 amino acid(s) of the CACNA1C protein. This variant is present in population databases (rs771708175, gnomAD 0.004%). This variant has not been reported in the literature in individuals affected with CACNA1C-related conditions. ClinVar contains an entry for this variant (Variation ID: 190695). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
AiLife Diagnostics, AiLife Diagnostics RCV002223803 SCV002503012 uncertain significance not provided 2021-11-21 criteria provided, single submitter clinical testing
Fulgent Genetics, Fulgent Genetics RCV002485068 SCV002775541 uncertain significance Timothy syndrome; Brugada syndrome 3; Long qt syndrome 8 2021-10-17 criteria provided, single submitter clinical testing
Ambry Genetics RCV003165344 SCV003855115 uncertain significance Cardiovascular phenotype 2023-02-14 criteria provided, single submitter clinical testing The c.6329dupG variant, located in coding exon 47 of the CACNA1C gene, results from a duplication of G at nucleotide position 6329, causing a translational frameshift with a predicted alternate stop codon (p.E2111Rfs*15). This alteration occurs at the 3' terminus of theCACNA1C gene, is not expected to trigger nonsense-mediated mRNAdecay, and only impacts the last 1% of the protein. The exact functional effect of this alteration is unknown. According to data from gnomAD, the frequency for this variant is above the maximum credible frequency for a cardiac disease-causing variant in this gene based on internally established thresholds (Karczewski et al. Nature. 2020 May;581(7809):434-443; Whiffin et al. Genet Med. 2017 10;19:1151-1158). Based on the supporting evidence, the association of this alteration with CACNA1C-related neurodevelopmental disorder is unknown; however, the association with CACNA1C-related Timothy syndrome or long QT syndrome is unlikely.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.